prior treatment with bsab does not impair response to car-t in patients with large b-cell lymphoma
Published 7 months ago • 107 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
2:02
impact of prior bendamustine exposure on bsab treatment outcomes in patients with b-cell lymphoma
-
1:31
bispecific antibodies in the treatment pipeline for myeloma in the uk
-
1:06
feasibility of treatment with bispecifics in patients with myeloma with prior bcma exposure
-
5:12
the emerging potential of bispecific antibodies as monotherapy & in combination for b-cell lymphoma
-
1:17
the promise of bispecific antibodies in the treatment of nhl
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:29
emerging lymphoma therapies: bispecific antibodies and car t-cells
-
1:01
considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
-
1:10:18
science: discovering antibodies in months: new advances in ht-spr, single-cell bcr-seq and rna-seq
-
38:40
bispecific antibodies in lymphoma: an update
-
1:00:37
biotalk: broadening b cell response using a nanoparticle adjuvant
-
3:23
session overview: improving treatment for patients with itp
-
1:20
improving outcomes of non-covalent btki treatment
-
3:05
car-t therapy in r/r dlbcl
-
1:36
patient selection in the treatment of nhl
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
-
1:52
improving the outcomes of transplantation with bispecific antibodies
-
1:52
how is bispecific antibody therapy changing myeloma care?
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
0:57
the potential of the tsafinder tool in hematological oncology